GKOS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Glaukos Corp (GKOS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has strong growth potential and positive analyst sentiment, the current technical indicators suggest a bearish trend, and the financial performance shows declining net income and EPS. The lack of immediate positive trading signals and the recent insider selling further support a cautious approach. Holding the stock or waiting for a better entry point would be more prudent.
The MACD histogram is negative and expanding (-1.678), indicating a bearish momentum. RSI is at 20.27, which is neutral but close to oversold territory. Moving averages are converging, suggesting no clear trend. The stock is trading near its support level (S1: 107.288), with resistance levels at R1: 121.17 and R2: 125.458. Overall, the technical indicators suggest a weak price trend.
FDA approval for repeat dosing of iDose, which broadens its label and supports long-term growth.
Analysts have raised price targets significantly, with targets as high as $160, citing strong growth potential in 2026 and beyond.
Hedge funds have significantly increased their buying activity (+318.02%).
Insiders have significantly increased their selling activity (+1898.23%), which could indicate a lack of confidence in near-term performance.
The stock has declined in both pre-market (-3.10%) and regular market (-2.10%) trading.
Financial performance shows declining net income (-24.19% YoY) and EPS (-28.21% YoY), despite revenue growth.
In Q3 2025, revenue increased by 38.14% YoY to $133.54M, showing strong top-line growth. However, net income dropped by 24.19% YoY to -$16.23M, and EPS fell by 28.21% YoY to -$0.28, indicating profitability challenges. Gross margin improved to 78.41%, up 2.31% YoY.
Analysts are highly positive on GKOS, with multiple firms raising price targets (e.g., Stifel to $160, BTIG to $131, Goldman Sachs to $138). The consensus is that the company has strong long-term growth potential, driven by FDA approvals and expanding market opportunities. However, the focus is on 2026 and beyond, with limited near-term catalysts.
